Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) received a positive opinion from the European Medicines Agency's CHMP for the booster dose of its bivalent Omicron-targeting COVID-19 vaccine, mRNA-1273.214, for children aged 6-11. The recommended pediatric dose is 12.5 mcg for both components, administered at least three months after the last vaccine dose. Clinical trials indicate that this booster elicits a stronger antibody response against the Omicron variant compared to previous vaccines. A Phase 2/3 trial for younger children is ongoing, with initial results expected in early 2023.

Moderna and Merck announced positive results from the Phase 2b KEYNOTE-942 trial of mRNA-4157/V940 combined with KEYTRUDA in stage III/IV melanoma patients. The study showed a 44% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone. This marks the first efficacy demonstration of an mRNA cancer treatment in a randomized trial. The companies plan to initiate a Phase 3 study and expand to other tumor types in 2023. Adverse events associated with mRNA-4157/V940 were consistent with previous studies, indicating manageable safety.

Moderna's mRNA-1273.222 has received Emergency Use Authorization (EUA) from the FDA for use in children aged 6 months to 5 years. This bivalent COVID-19 booster vaccine targets the BA.4/BA.5 Omicron variants and is based on clinical trial data showing stronger antibody responses compared to the original vaccine. The EUA extends to pediatric use and has been supported by data from earlier trials. Moderna is also conducting ongoing trials for broader age groups, with results expected in early 2023.

Moderna, Inc. (NASDAQ:MRNA) announces Brad Miller as the new Chief Information Officer effective January 3, taking over from retiring Chief Digital Officer Marcello Damiani in March. Miller brings extensive experience from Capital One, Mastercard, Citibank, Amazon, and Microsoft. His expertise in digital solutions is expected to support Moderna’s growth in mRNA therapeutics and vaccines. Moderna has transitioned over 10 years from a research-stage company to a leading biopharmaceutical entity, recognized for its COVID-19 vaccine and diverse clinical portfolio.

Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 9:00 a.m. ET. A live webcast can be accessed in the 'Events and Presentations' section of its investors website, with a replay available for 30 days post-event. Over the past decade, Moderna has evolved from a research company to a leader in mRNA therapeutics and vaccines, significantly contributing to COVID-19 solutions. For more information, visit modernatx.com.

Moderna (NASDAQ: MRNA) has appointed David Jiménez as General Manager for the United States, effective November 21, 2022. Jiménez brings over two decades of experience from Johnson & Johnson, where he led significant pharmaceutical franchises, including a $10+ billion U.S. Immunology franchise. His expertise is expected to be crucial as Moderna transitions to a commercial vaccine market in the U.S. and develops new candidates in 2023. Moderna's approach to messenger RNA technology continues to impact the COVID-19 pandemic significantly.

Moderna (NASDAQ:MRNA) has been ranked the number one large employer in BioSpace's 2023 Best Places to Work report, marking its second consecutive year in this position. CEO Stéphane Bancel highlighted the company's commitment to culture, equity, and diversity, noting a workforce of over 3,800 employees with gender parity achieved in September 2022. Moderna continues to focus on employee development through initiatives like Moderna University. The recognition is based on responses from more than 2,000 life sciences professionals, showcasing the company's strong reputation in the biopharma sector.

Moderna announced in a press release dated November 14, 2022, that its bivalent booster candidates, mRNA-1273.214 and mRNA-1273.222, have shown superior neutralizing antibody responses against Omicron variants BA.4/BA.5 in a Phase 2/3 trial involving over 500 adults. Results indicated a 15.1-fold increase in geometric mean titers for mRNA-1273.222 compared to the original booster. Both vaccines demonstrated comparable safety profiles with fewer adverse events than previous doses. This builds on earlier findings published in the New England Journal of Medicine, confirming the effectiveness of these updated vaccine candidates.